JPMorgan Chase & Co. Cuts Omnicell (NASDAQ:OMCL) Price Target to $36.00

Omnicell (NASDAQ:OMCL) had its price target decreased by JPMorgan Chase & Co. from $44.00 to $36.00 in a research note issued on Thursday,Benzinga reports. The firm currently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price target points to a potential upside of 2.89% from the stock’s previous close.

OMCL has been the subject of a number of other reports. Bank of America decreased their price target on Omnicell from $54.00 to $46.00 and set a “neutral” rating on the stock in a research report on Monday, January 6th. StockNews.com upgraded Omnicell from a “hold” rating to a “buy” rating in a research report on Thursday, March 6th. Benchmark restated a “buy” rating and set a $62.00 price target on shares of Omnicell in a research report on Tuesday, February 4th. Finally, Wells Fargo & Company decreased their price target on Omnicell from $49.00 to $40.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $51.00.

Omnicell Price Performance

Shares of OMCL traded up $0.29 during mid-day trading on Thursday, reaching $34.99. The company had a trading volume of 78,386 shares, compared to its average volume of 491,190. Omnicell has a twelve month low of $25.12 and a twelve month high of $55.75. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.37 and a quick ratio of 1.22. The company’s 50-day moving average is $40.10 and its 200-day moving average is $43.04. The company has a market capitalization of $1.64 billion, a P/E ratio of 129.52, a P/E/G ratio of 7.53 and a beta of 0.85.

Omnicell (NASDAQ:OMCL) last issued its earnings results on Thursday, February 6th. The company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. On average, equities analysts anticipate that Omnicell will post 1.09 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in Omnicell by 0.5% in the 4th quarter. Vanguard Group Inc. now owns 5,562,165 shares of the company’s stock valued at $247,628,000 after buying an additional 28,573 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Omnicell by 31.6% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,642,626 shares of the company’s stock worth $73,127,000 after purchasing an additional 394,820 shares during the last quarter. Lazard Asset Management LLC boosted its position in shares of Omnicell by 81.6% in the 4th quarter. Lazard Asset Management LLC now owns 1,641,817 shares of the company’s stock worth $73,093,000 after purchasing an additional 737,536 shares during the last quarter. Victory Capital Management Inc. boosted its position in shares of Omnicell by 32.9% in the 4th quarter. Victory Capital Management Inc. now owns 1,526,309 shares of the company’s stock worth $67,951,000 after purchasing an additional 377,883 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. boosted its position in shares of Omnicell by 93.3% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,450,416 shares of the company’s stock worth $64,573,000 after purchasing an additional 699,925 shares during the last quarter. 97.70% of the stock is currently owned by institutional investors.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.